SARRC's Research Department is committed to identifying best practices for autism spectrum disorder (ASD) screening, diagnosis, and intervention, but we cannot do it alone. We look to individuals impacted by autism and their families to participate in our current research projects. Our research program utilizes rigorous research methods and is informed by the needs, preferences, and values of the community that we serve. Note: A stipend may be provided to cover the cost of time and travel.
The Acadia Study is a 14-week study to learn about irritability associated with autism spectrum disorder (ASD). We are enrolling individuals with an autism diagnosis ages 5-17 for this clinical study involving an investigational medication. The purpose of this study is to evaluate the effectiveness and safety of the study medication for the treatment of irritability associated with ASD, as well as the efficacy in the treatment of other symptoms associated with ASD, such as social and communication benefits and repetitive behaviors. Learn more »
Aging & Autism Study
In partnership with Barrow Neurological Institute (BNI), SARRC is studying the aging process of individuals with ASD. SARRC is recruiting participants with a diagnosis of ASD and without ASD including men 40-70 years old and women ages 18-70 years old. Participants are asked to complete an evaluation at SARRC and then undergo an FMRI scan at BNI. During the scan, participants will complete tasks related to memory and thinking.
To enroll, please contact the Autism Brain Aging Lab directly at 480.727.3970 or firstname.lastname@example.org
The Aurora Study is a clinical study using an investigational medication for core symptoms of ASD. SARRC is currently enrolling individuals between ages 15-45 who have a diagnosis of ASD to participate in a clinical study that aims to evaluate the effectiveness of an investigational medication to help treat social and/or communication deficits and symptoms of repetitive behaviors in adults with ASD. Learn more »
We are currently looking for participants ages 6-17 with Attention-deficit/Hyperactivity Disorder (ADHD) for an open-label clinical trial involving an investigational drug. The purpose of this study is to evaluate the long-term safety and tolerability of the study drug, Centanafadine, for the treatment of children and adolescents experiencing ADHD symptoms, such as hyperactivity, inattentiveness and impulsivity. Interested participants do not need to have a professional diagnosis of ADHD to enroll. Learn more »
In the IRIS research study, we are looking to find out whether an investigational drug might improve the symptoms of ASD that often make social interaction challenging. To qualify, participants must be 18 to 45 years of age; have a diagnosis of autism spectrum disorder (ASD) have a relative, housemate, friend, or another study partner to assist during the study, and attend clinic visits. Learn more »
Mindfulness-Based Intervention Study
We are currently recruiting teens ages 13-18 with an autism diagnosis and without an intellectual disability (IQ of 70 or above) and at least one parent or caregiver to participate in a study of a mindfulness-based intervention called MINDful Time (Mindfulness-based Intervention for NeuroDiverse teens: Telehealth Instruction, Mobile app Enhanced). The purpose of this study is to evaluate whether participation in MINDful Time reduces stress, anxiety or depressive symptoms for teens and their parents. The Mindfulness-Based Intervention Study is offered in a virtual setting. Learn more »
National Institute of Mental Health Outcomes Study
Learn about your child’s development and academic strengths in the NIMH Outcomes Study. In partnership with UCSD, SARRC is examining the developmental progress and benefits of early intervention in children with autism 6-10 years old. You will receive compensation for your participation. Learn more »
A snapshot of your participation includes:
- Free comprehensive evaluation provided by a licensed clinical psychologist.
- Questionnaires about a child’s treatment, school placement and performance, and specific areas of functioning.
- Visits will be completed on our 16th Street Phoenix campus, following strict COVID safety policies.
- Families will receive $100 and a written summary of test results.
We are currently enrolling adolescents ages 13 to 17 to participate in a clinical study that is investigating a medication designed to remove bacterial chemicals produced in the gut that may reach the brain resulting in characteristics associated with ASD. The purpose of this study is to evaluate the safety and effectiveness of an investigational medication to potentially improve symptoms associated with ASD such as irritability and anxiety and evaluate changes in sleep, and quality of life. Learn more »
SPARK for Autism
The Simons Foundation Autism Research Initiative is offering SPARK—an online, long-term study of genetics and autism. SPARK will collect and analyze genetic samples (saliva) from all participants to help autism researchers learn about genetic and non-genetic causes of autism. SPARK is open to all individuals with a professional diagnosis of autism, as well as their parents. Participation can take place either in your home via mail-in kit or at SARRC. Learn more »
Yamo Study: Potential Treatment for Social Difficulties
This study will evaluate an investigational medication to improve social communication and interactions in adolescents and young adults ages 12-21 with an autism diagnosis.
This medication could potentially improve social communication skills in adolescents and young adults with ASD. In this study, all participants will receive the study medication for a period of time, either at the beginning or the end of the study period. Learn more »